BioCentury
ARTICLE | Clinical News

AXS-05: Phase III started

March 28, 2016 7:00 AM UTC

Axsome began the double-blind Phase III STRIDE-1 trial to compare oral AXS-05 vs. bupropion in about 300 MDD patients who failed 1-2 antidepressant treatments. Patients will receive bupropion for 6 we...